A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
for Relapsed/Refractory Multiple Myeloma
Drug: Daratumumab
16 locations incl. Birmingham
Sponsor: BeOne Medicines
Sex: All·Age: 18+
Code: NCT04973605·Phase 1, Phase 2·Recruiting